Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Arturo Casadevall and Liise-Anne Pirofski.
Arturo Casadevall
Connection Strength
10.877
Liise-Anne Pirofski
  1. Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy. Clin Infect Dis. 2021 08 02; 73(3):e540-e542.
    View in: PubMed
    Score: 0.960
  2. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. J Clin Invest. 2021 04 01; 131(7).
    View in: PubMed
    Score: 0.938
  3. Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. N Engl J Med. 2021 01 14; 384(2):189.
    View in: PubMed
    Score: 0.921
  4. In fatal COVID-19, the immune response can control the virus but kill the patient. Proc Natl Acad Sci U S A. 2020 12 01; 117(48):30009-30011.
    View in: PubMed
    Score: 0.913
  5. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. J Clin Invest. 2020 10 01; 130(10):5112-5114.
    View in: PubMed
    Score: 0.906
  6. A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals. JAMA. 2020 08 04; 324(5):455-457.
    View in: PubMed
    Score: 0.896
  7. Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework. mBio. 2020 07 02; 11(4).
    View in: PubMed
    Score: 0.890
  8. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 04 01; 130(4):1545-1548.
    View in: PubMed
    Score: 0.875
  9. The Damage-Response Framework as a Tool for the Physician-Scientist to Understand the Pathogenesis of Infectious Diseases. J Infect Dis. 2018 08 14; 218(suppl_1):S7-S11.
    View in: PubMed
    Score: 0.781
  10. A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis. Clin Infect Dis. 2018 06 01; 66(12):1937-1939.
    View in: PubMed
    Score: 0.770
  11. What Is a Host? Attributes of Individual Susceptibility. Infect Immun. 2018 02; 86(2).
    View in: PubMed
    Score: 0.752
  12. Immunomodulators as an antimicrobial tool. Curr Opin Microbiol. 2006 Oct; 9(5):489-95.
    View in: PubMed
    Score: 0.341
  13. COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses. 2021 08 11; 13(8).
    View in: PubMed
    Score: 0.240
  14. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. mBio. 2021 03 02; 12(2).
    View in: PubMed
    Score: 0.233
  15. The Assessment of Convalescent Plasma Efficacy against COVID-19. Med (N Y). 2020 Dec 18; 1(1):66-77.
    View in: PubMed
    Score: 0.230
  16. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne). 2021; 8:684151.
    View in: PubMed
    Score: 0.059
  17. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021 08; 61(8):2503-2511.
    View in: PubMed
    Score: 0.059
  18. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 05; 96(5):1262-1275.
    View in: PubMed
    Score: 0.058
  19. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 06 01; 130(6):2757-2765.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.